The Possible Future Roles for iPSC-Derived Therapy for Autoimmune Diseases

Journal of Clinical Medicine

Meilyn Hew²  Kevin O𠆜onnor³  Michael J. Edel¹  Michaela Lucas² 

[1] Control of Pluripotency Laboratory, Department of Physiological Sciences I, Faculty of Medicine, University of Barcelona, Hospital Clinic, Casanova 143, Barcelona 08036, Spain; E-Mail:;Department of Clinical Immunology, Pathwest Laboratory Medicine, Queen Elizabeth II Medical Centre, Perth 6009, Western Australia, Australia; E-Mail:;Department of Clinical Immunology, Royal Perth Hospital, Perth 6000, Western Australia, Australia; E-Mail:

关键词: inducible;    pluripotent;    stem cells;    autoimmunity;    therapy;    lupus;    diabetes;    multiple sclerosis;   

DOI  :  10.3390/jcm4061193

来源: mdpi

【 摘 要 】

The ability to generate inducible pluripotent stem cells (iPSCs) and the potential for their use in treatment of human disease is of immense interest. Autoimmune diseases, with their limited treatment choices are a potential target for the clinical application of stem cell and iPSC technology. IPSCs provide three potential ways of treating autoimmune disease; (i) providing pure replacement of lost cells (immuno-reconstitution); (ii) through immune-modulation of the disease process in vivo; and (iii) for the purposes of disease modeling in vitro. In this review, we will use examples of systemic, system-specific and organ-specific autoimmunity to explore the potential applications of iPSCs for treatment of autoimmune diseases and review the evidence of iPSC technology in auto-immunity to date.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.